APOBEC3C and nonpapillary renal cell carcinoma: Cells with depleted levels of A3C exhibited significantly reduced viability when treated with Pazopanib or Sunitinib (Fig. S7I), indicating that ccRCC‐derived cells may become more susceptible to tyrosine kinase inhibitor treatment upon A3C depletion or inhibition.